Rizatriptan is a selective agonist of serotonin (5-hydroxytryptamine; 5-HT) type 1B and 1D receptors. It is structurally and pharmacologically related to other selective 5-HT1B/1D receptor agonists and has only a weak affinity for 5-HT_1A, 5-HT_5A, and 5-HT₇ receptors and no significant affinity or pharmacological activity at 5-HT₂, 5-HT₃ or 5-HT₄ receptor subtypes or at alpha1-, alpha2-, or beta-adrenergic, dopamine1,; dopamine2; muscarinic, or benzodiazepine receptors. This action in humans correlates with the relief of migraine headache. In addition to causing vasoconstriction, experimental data from animal studies show that Rizatriptan also activates 5-HT₁ receptors on peripheral terminals of the trigeminal nerve innervating cranial blood vessels, which may also contribute to the antimigrainous effect of Rizatriptan in humans.

Mechanism of action

Three distinct pharmacological actions have been implicated in the antimigraine effect of the triptans: (1) stimulation of presynaptic 5-HT1D receptors, which serves to inhibit both dural vasodilation and inflammation; (2) direct inhibition of trigeminal nuclei cell excitability via 5-HT1B/1D receptor agonism in the brainstem and (3) vasoconstriction of meningeal, dural, cerebral or pial vessels as a result of vascular 5-HT1B receptor agonism.

Target	Actions	Organism
A5-hydroxytryptamine receptor 1D	agonist	Humans
A5-hydroxytryptamine receptor 1B	agonist	Humans
A5-hydroxytryptamine receptor 1F	agonist	Humans

Absorption

Rapid following oral administration. Bioavailability is 45%. Food has no effect on the bioavailability of rizatriptan. However, administering rizatriptan with food will delay by 1 hour the time to reach peak plasma concentration. The rate of absorption is not affected by the presence of a migraine attack.

Volume of distribution

140 L [male]
110 L [female]

Protein binding

14%

Metabolism

Rizatriptan is metabolized by monoamine oxidase A isoenzyme (MAO-A) to an inactive indole acetic acid metabolite. In addition, several other inactive metabolites are formed. An active metabolite, N-monodesmethyl-rizatriptan, with pharmacological activity similar to that of the parent compound has been identified in small concentrations (14%) in the plasma.

Hover over products below to view reaction partners

Rizatriptan
- N-monodesmethyl-rizatriptan

Route of elimination

Approximately 14% of an oral dose is excreted in urine as unchanged rizatriptan while 51% is excreted as indole acetic acid metabolite, indicating substantial first pass metabolism.

Half-life

2-3 hours

Clearance

Not Available

Adverse Effects

Improve decision support & research outcomes

With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.

Learn more

Improve decision support & research outcomes with our structured adverse effects data.

Learn more

Toxicity

Symptoms of overdose include dizziness, fainting, heart and blood vessel problems, high blood pressure, loss of bowel and bladder control, slow heartbeat, and vomiting.

Pathways

Not Available

Pharmacogenomic Effects/ADRs

Interacting Gene/Enzyme	Allele name	Genotype(s)	Defining Change(s)	Type(s)	Description	Details
Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-3	---	(C;T) / (T;T)	T Allele	Effect Directly Studied	Patients with this genotype have an increased likelihood of responding to rizatriptan when treating (condition: cluster headache).	Details

Interactions

Drug Interactions

This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.

Drug	Interaction
Integrate drug-drug interactions in your software
1,2-Benzodiazepine	The risk or severity of adverse effects can be increased when Rizatriptan is combined with 1,2-Benzodiazepine.
Abacavir	Rizatriptan may decrease the excretion rate of Abacavir which could result in a higher serum level.
Acebutolol	Rizatriptan may decrease the antihypertensive activities of Acebutolol.
Aceclofenac	The risk or severity of hypertension can be increased when Rizatriptan is combined with Aceclofenac.
Acemetacin	The risk or severity of hypertension can be increased when Rizatriptan is combined with Acemetacin.
Acenocoumarol	The risk or severity of adverse effects can be increased when Rizatriptan is combined with Acenocoumarol.
Acetaminophen	Acetaminophen may decrease the excretion rate of Rizatriptan which could result in a higher serum level.
Acetazolamide	The risk or severity of adverse effects can be increased when Acetazolamide is combined with Rizatriptan.
Acetophenazine	The risk or severity of adverse effects can be increased when Rizatriptan is combined with Acetophenazine.
Acetylsalicylic acid	The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Rizatriptan.

Identify potential medication risks

Easily compare up to 40 drugs with our drug interaction checker.

Get severity rating, description, and management advice.

Learn more

Food Interactions

Take with or without food. However, the onset of action may be delayed by approximately 1 hour when taken with food.

Products

Drug product information from 10+ global regions

Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.

Access now

Access drug product information from over 10 global regions.

Access now

Product Ingredients

Ingredient	UNII	CAS	InChI Key
Rizatriptan benzoate	WR978S7QHH	145202-66-0	JPRXYLQNJJVCMZ-UHFFFAOYSA-N

Product Images

International/Other Brands

Maxalt MLT

Brand Name Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Act Rizatriptan	Tablet	10 mg	Oral	TEVA Canada Limited	2012-06-14	Not applicable
Act Rizatriptan	Tablet	5 mg	Oral	TEVA Canada Limited	Not applicable	Not applicable
Act Rizatriptan ODT	Tablet, orally disintegrating	10 mg	Oral	Actavis Pharma Company	2012-01-30	2019-08-08
Act Rizatriptan ODT	Tablet, orally disintegrating	5 mg	Oral	Actavis Pharma Company	2012-01-30	2019-08-08
Maxalt	Tablet	5 mg/1	Oral	Merck Sharp & Dohme Corp.	1998-06-29	2017-12-31
Maxalt	Tablet	10 mg	Oral	Organon Canada Inc.	1999-08-31	Not applicable
Maxalt	Tablet	10 mg/1	Oral	Stat Rx USA	1998-06-29	Not applicable
Maxalt	Tablet	10 mg/1	Oral	Lake Erie Medical Dba Quality Care Produts Llc	2007-08-24	2014-12-31
Maxalt	Tablet	10 mg/1	Oral	Organon LLC	2021-06-01	Not applicable
Maxalt	Tablet	10 mg/1	Oral	Merck Sharp & Dohme Corp.	1998-06-29	Not applicable

Generic Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Accel-rizatriptan ODT	Tablet, orally disintegrating	5 mg	Oral	Accel Pharma Inc	2019-10-07	Not applicable
Accel-rizatriptan ODT	Tablet, orally disintegrating	10 mg	Oral	Accel Pharma Inc	2019-10-07	Not applicable
Ag-rizatriptan ODT	Tablet, orally disintegrating	10 mg	Oral	Angita Pharma Inc.	2020-01-27	Not applicable
Ag-rizatriptan ODT	Tablet, orally disintegrating	5 mg	Oral	Angita Pharma Inc.	2021-08-06	Not applicable
Apo-rizatriptan	Tablet	5 mg	Oral	Apotex Corporation	2013-03-06	Not applicable
Apo-rizatriptan	Tablet	10 mg	Oral	Apotex Corporation	2012-09-27	Not applicable
Apo-rizatriptan Rpd	Tablet, orally disintegrating	5 mg	Oral	Apotex Corporation	2013-09-10	Not applicable
Apo-rizatriptan Rpd	Tablet, orally disintegrating	10 mg	Oral	Apotex Corporation	2013-09-10	Not applicable
Auro-rizatriptan	Tablet	10 mg	Oral	Auro Pharma Inc	2016-04-12	Not applicable
Auro-rizatriptan ODT	Tablet, orally disintegrating	10 mg	Oral	Auro Pharma Inc	Not applicable	Not applicable

Chemical Identifiers

UNII: 51086HBW8G
CAS number: 144034-80-0
InChI Key: ULFRLSNUDGIQQP-UHFFFAOYSA-N
InChI: InChI=1S/C15H19N5/c1-19(2)6-5-13-8-17-15-4-3-12(7-14(13)15)9-20-11-16-10-18-20/h3-4,7-8,10-11,17H,5-6,9H2,1-2H3
IUPAC Name: dimethyl(2-{5-[(1H-1,2,4-triazol-1-yl)methyl]-1H-indol-3-yl}ethyl)amine
SMILES: CN(C)CCC1=CNC2=C1C=C(CN1C=NC=N1)C=C2

References

Synthesis Reference

Montserrat Armengol Asparo, Pere Dalmases Barjoan, "Process for preparing a rizatriptan." U.S. Patent US20050148778, issued July 07, 2005.

US20050148778

General References

Wellington K, Plosker GL: Rizatriptan: an update of its use in the management of migraine. Drugs. 2002;62(10):1539-74. [Article]
Wellington K, Jarvis B: Spotlight on rizatriptan in migraine. CNS Drugs. 2002;16(10):715-20. [Article]
Ikemoto F, Toru T, Aijima H, Natsumeda Y: [Rizatriptan (Maxalt), a new entity of triptan for migraine: pharmacology and therapeutic relevance]. Nihon Yakurigaku Zasshi. 2004 Apr;123(4):295-302. [Article]
Villalon CM, Centurion D, Valdivia LF, De Vries P, Saxena PR: An introduction to migraine: from ancient treatment to functional pharmacology and antimigraine therapy. Proc West Pharmacol Soc. 2002;45:199-210. [Article]
Tfelt-Hansen P, De Vries P, Saxena PR: Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy. Drugs. 2000 Dec;60(6):1259-87. [Article]

External Links

Human Metabolome Database: HMDB0015088
KEGG Drug: D00675
PubChem Compound: 5078
PubChem Substance: 46506557
ChemSpider: 4900
BindingDB: 50033437
RxNav: 88014
ChEBI: 48273
ChEMBL: CHEMBL905
ZINC: ZINC000000005895
Therapeutic Targets Database: DAP000220
PharmGKB: PA451264
Guide to Pharmacology: GtP Drug Page
RxList: RxList Drug Page
Drugs.com: Drugs.com Drug Page
PDRhealth: PDRhealth Drug Page
Wikipedia: Rizatriptan

FDA label

Download (873 KB)

MSDS

Download (57.7 KB)

Clinical Trials

Clinical Trials

Phase	Status	Purpose	Conditions	Count
4	Completed	Basic Science	Episodic Migraine	1
4	Completed	Other	Workplace Migraine Treatment	1
4	Completed	Treatment	Migraine	3
3	Completed	Treatment	Acute Migraine	2
3	Completed	Treatment	Acute Migraine With or Without Aura in Adolescents	1
3	Completed	Treatment	Migraine	16
3	Completed	Treatment	Migraine With Aura / Migraine Without Aura	1
3	Not Yet Recruiting	Treatment	Migraine	1
2	Completed	Treatment	Migraine	1
2, 3	Completed	Treatment	Migrainous Vertigo / Vestibular Migraine	1

Pharmacoeconomics

Manufacturers

Merck and co inc

Packagers

Catalent Pharma Solutions
Chunghwa Chemical Synthesis and Biotech Co. Ltd.
Diversified Healthcare Services Inc.
Lake Erie Medical and Surgical Supply
Merck & Co.
Nucare Pharmaceuticals Inc.
Physicians Total Care Inc.
Scherer Drug Delivery Systems Ltd.

Dosage Forms

Form	Route	Strength
Tablet	Oral	5 mg
Film, soluble	Oral
Film, soluble	Oral	10 mg
Film, soluble	Oral	5 mg
Tablet	Oral
Tablet	Oral	10 mg
Tablet	Oral	10 mg/1
Tablet		10 mg
Tablet		5 mg
Tablet, orally disintegrating	Oral	10 mg
Tablet, orally disintegrating	Oral	5 mg
Tablet, orally disintegrating	Oral	10 mg/1
Tablet, orally disintegrating	Oral	5 mg/1
Tablet, effervescent
Gel	Oral	10 MG
Tablet, film coated	Oral	10 mg/1
Tablet, film coated	Oral	5 mg/1
Tablet, orally disintegrating	Oral
Tablet	Oral	5 mg/1
Tablet	Oropharyngeal	10 mg/1
Tablet

Prices

Unit description	Cost	Unit
Maxalt 12 10 mg tablet Box	333.27USD	box
Maxalt 12 5 mg tablet Box	333.27USD	box
Maxalt-MLT 3 5 mg Dispersible Tablet Box	286.96USD	box
Maxalt 9 5 mg tablet Box	203.46USD	box
Maxalt 6 5 mg tablet Box	107.44USD	box
Maxalt-MLT 3 10 mg Dispersible Tablet Box	83.32USD	box
Maxalt mlt 10 mg tablet	26.7USD	tablet
Maxalt mlt 5 mg tablet	26.7USD	tablet
Maxalt 10 mg tablet	25.31USD	tablet
Maxalt 5 mg tablet	22.98USD	tablet

DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.

Patents

Patent Number	Pediatric Extension	Approved	Expires (estimated)
US5602162	No	1997-02-11	2014-02-11
US5298520	No	1994-03-29	2012-06-29
CA2060139	No	1998-12-01	2012-01-28

Properties

State

Solid

Experimental Properties

Property	Value	Source
melting point (°C)	178-180 °C	Not Available
water solubility	42 mg/mL (for free base)	Not Available
logP	1.4	Not Available

Predicted Properties

Property	Value	Source
Water Solubility	0.338 mg/mL	ALOGPS
logP	1.67	ALOGPS
logP	1.77	ChemAxon
logS	-2.9	ALOGPS
pKa (Strongest Acidic)	17.23	ChemAxon
pKa (Strongest Basic)	9.56	ChemAxon
Physiological Charge	1	ChemAxon
Hydrogen Acceptor Count	3	ChemAxon
Hydrogen Donor Count	1	ChemAxon
Polar Surface Area	49.74 Å²	ChemAxon
Rotatable Bond Count	5	ChemAxon
Refractivity	93.13 m³·mol^-1	ChemAxon
Polarizability	30 Å³	ChemAxon
Number of Rings	3	ChemAxon
Bioavailability	1	ChemAxon
Rule of Five	Yes	ChemAxon
Ghose Filter	Yes	ChemAxon
Veber's Rule	No	ChemAxon
MDDR-like Rule	No	ChemAxon

Predicted ADMET Features

Property	Value	Probability
Human Intestinal Absorption	+	1.0
Blood Brain Barrier	+	0.9406
Caco-2 permeable	+	0.5547
P-glycoprotein substrate	Substrate	0.7478
P-glycoprotein inhibitor I	Non-inhibitor	0.8752
P-glycoprotein inhibitor II	Non-inhibitor	0.7244
Renal organic cation transporter	Inhibitor	0.7394
CYP450 2C9 substrate	Non-substrate	0.8572
CYP450 2D6 substrate	Non-substrate	0.6765
CYP450 3A4 substrate	Substrate	0.5574
CYP450 1A2 substrate	Non-inhibitor	0.9149
CYP450 2C9 inhibitor	Non-inhibitor	0.9063
CYP450 2D6 inhibitor	Non-inhibitor	0.8913
CYP450 2C19 inhibitor	Non-inhibitor	0.9515
CYP450 3A4 inhibitor	Non-inhibitor	0.9688
CYP450 inhibitory promiscuity	Low CYP Inhibitory Promiscuity	0.956
Ames test	AMES toxic	0.5644
Carcinogenicity	Non-carcinogens	0.9133
Biodegradation	Not ready biodegradable	0.9439
Rat acute toxicity	2.5433 LD50, mol/kg	Not applicable
hERG inhibition (predictor I)	Weak inhibitor	0.7051
hERG inhibition (predictor II)	Non-inhibitor	0.7265

ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)

Not Available

Spectra

Spectrum	Spectrum Type	Splash Key
Predicted GC-MS Spectrum - GC-MS	Predicted GC-MS	Not Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
LC-MS/MS Spectrum - LC-ESI-qTof , Positive	LC-MS/MS	Not Available
MS/MS Spectrum - , positive	LC-MS/MS	splash10-0udi-0590000000-de0b61f549c5a86c98df

Targets

Build, predict & validate machine-learning models

Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.

Learn more

Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.

Learn more

Property	Measurement	pH	Temperature (°C)	References
EC 50 (nM)	3	N/A	N/A	A28741
EC 50 (nM)	8.4	N/A	N/A	A28746
IC 50 (nM)	11	N/A	N/A	A28746
IC 50 (nM)	79.43	N/A	N/A	A28734
Ki (nM)	14	N/A	N/A	A27734
Ki (nM)	4.3	N/A	N/A	A28741
Ki (nM)	40	N/A	N/A	A27734

Details1. 5-hydroxytryptamine receptor 1D

Kind: Protein
Organism: Humans
Pharmacological action: Yes
Actions: Agonist

General Function: Serotonin receptor activity
Specific Function: G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive subst...
Gene Name: HTR1D
Uniprot ID: P28221
Uniprot Name: 5-hydroxytryptamine receptor 1D
Molecular Weight: 41906.38 Da

References

Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [Article]
Longmore J, Hargreaves RJ, Boulanger CM, Brown MJ, Desta B, Ferro A, Schofield WN, Taylor AA, Hill RG: Comparison of the vasoconstrictor properties of the 5-HT1D-receptor agonists rizatriptan (MK-462) and sumatriptan in human isolated coronary artery: outcome of two independent studies using different experimental protocols. Funct Neurol. 1997 Jan-Feb;12(1):3-9. [Article]
Longmore J, Boulanger CM, Desta B, Hill RG, Schofield WN, Taylor AA: 5-HT1D receptor agonists and human coronary artery reactivity in vitro: crossover comparisons of 5-HT and sumatriptan with rizatriptan and L-741,519. Br J Clin Pharmacol. 1996 Oct;42(4):431-41. [Article]
Sciberras DG, Polvino WJ, Gertz BJ, Cheng H, Stepanavage M, Wittreich J, Olah T, Edwards M, Mant T: Initial human experience with MK-462 (rizatriptan): a novel 5-HT1D agonist. Br J Clin Pharmacol. 1997 Jan;43(1):49-54. [Article]
Williamson DJ, Hill RG, Shepheard SL, Hargreaves RJ: The anti-migraine 5-HT(1B/1D) agonist rizatriptan inhibits neurogenic dural vasodilation in anaesthetized guinea-pigs. Br J Pharmacol. 2001 Aug;133(7):1029-34. [Article]
Wackenfors A, Jarvius M, Ingemansson R, Edvinsson L, Malmsjo M: Triptans induce vasoconstriction of human arteries and veins from the thoracic wall. J Cardiovasc Pharmacol. 2005 May;45(5):476-84. [Article]
Wellington K, Plosker GL: Rizatriptan: an update of its use in the management of migraine. Drugs. 2002;62(10):1539-74. [Article]
Wellington K, Jarvis B: Spotlight on rizatriptan in migraine. CNS Drugs. 2002;16(10):715-20. [Article]
Ikemoto F, Toru T, Aijima H, Natsumeda Y: [Rizatriptan (Maxalt), a new entity of triptan for migraine: pharmacology and therapeutic relevance]. Nihon Yakurigaku Zasshi. 2004 Apr;123(4):295-302. [Article]

Property	Measurement	pH	Temperature (°C)	References
IC 50 (nM)	41	N/A	N/A	A28746
Ki (nM)	10.1	N/A	N/A	A28741

Details2. 5-hydroxytryptamine receptor 1B

Kind: Protein
Organism: Humans
Pharmacological action: Yes
Actions: Agonist

General Function: Serotonin receptor activity
Specific Function: G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive subst...
Gene Name: HTR1B
Uniprot ID: P28222
Uniprot Name: 5-hydroxytryptamine receptor 1B
Molecular Weight: 43567.535 Da

References

Wellington K, Plosker GL: Rizatriptan: an update of its use in the management of migraine. Drugs. 2002;62(10):1539-74. [Article]
Wellington K, Jarvis B: Spotlight on rizatriptan in migraine. CNS Drugs. 2002;16(10):715-20. [Article]
Ikemoto F, Toru T, Aijima H, Natsumeda Y: [Rizatriptan (Maxalt), a new entity of triptan for migraine: pharmacology and therapeutic relevance]. Nihon Yakurigaku Zasshi. 2004 Apr;123(4):295-302. [Article]
Pauwels PJ, Palmier C, Dupuis DS, Colpaert FC: Interaction of 5-HT1B/D ligands with recombinant h 5-HT1A receptors: intrinsic activity and modulation by G-protein activation state. Naunyn Schmiedebergs Arch Pharmacol. 1998 May;357(5):490-9. [Article]
Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [Article]
Williamson DJ, Hill RG, Shepheard SL, Hargreaves RJ: The anti-migraine 5-HT(1B/1D) agonist rizatriptan inhibits neurogenic dural vasodilation in anaesthetized guinea-pigs. Br J Pharmacol. 2001 Aug;133(7):1029-34. [Article]
Wackenfors A, Jarvius M, Ingemansson R, Edvinsson L, Malmsjo M: Triptans induce vasoconstriction of human arteries and veins from the thoracic wall. J Cardiovasc Pharmacol. 2005 May;45(5):476-84. [Article]

Details3. 5-hydroxytryptamine receptor 1F

Kind: Protein
Organism: Humans
Pharmacological action: Yes
Actions: Agonist

General Function: Serotonin receptor activity
Specific Function: G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various alkaloids and psychoactive substances. Ligand binding causes a conformation change that trig...
Gene Name: HTR1F
Uniprot ID: P30939
Uniprot Name: 5-hydroxytryptamine receptor 1F
Molecular Weight: 41708.505 Da

References

Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [Article]
Villalon CM, Centurion D, Valdivia LF, de Vries P, Saxena PR: Migraine: pathophysiology, pharmacology, treatment and future trends. Curr Vasc Pharmacol. 2003 Mar;1(1):71-84. [Article]
Villalon CM, Centurion D, Valdivia LF, De Vries P, Saxena PR: An introduction to migraine: from ancient treatment to functional pharmacology and antimigraine therapy. Proc West Pharmacol Soc. 2002;45:199-210. [Article]
Wainscott DB, Johnson KW, Phebus LA, Schaus JM, Nelson DL: Human 5-HT1F receptor-stimulated [35S]GTPgammaS binding: correlation with inhibition of guinea pig dural plasma protein extravasation. Eur J Pharmacol. 1998 Jul 3;352(1):117-24. [Article]
Goadsby PJ, Classey JD: Evidence for serotonin (5-HT)1B, 5-HT1D and 5-HT1F receptor inhibitory effects on trigeminal neurons with craniovascular input. Neuroscience. 2003;122(2):491-8. [Article]

Enzymes

Details1. Amine oxidase [flavin-containing] A

Kind: Protein
Organism: Humans
Pharmacological action: Unknown
Actions: Substrate

General Function: Serotonin binding
Specific Function: Catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral...
Gene Name: MAOA
Uniprot ID: P21397
Uniprot Name: Amine oxidase [flavin-containing] A
Molecular Weight: 59681.27 Da

References

Iwasa T, Sano H, Sugiura A, Uchiyama N, Hara K, Okochi H, Nakagawa K, Yasumori T, Ishizaki T: An in vitro interethnic comparison of monoamine oxidase activities between Japanese and Caucasian livers using rizatriptan, a serotonin receptor 1B/1D agonist, as a model drug. Br J Clin Pharmacol. 2003 Nov;56(5):537-44. [Article]
Van Haarst AD, Van Gerven JM, Cohen AF, De Smet M, Sterrett A, Birk KL, Fisher AL, De Puy ME, Goldberg MR, Musson DG: The effects of moclobemide on the pharmacokinetics of the 5-HT1B/1D agonist rizatriptan in healthy volunteers. Br J Clin Pharmacol. 1999 Aug;48(2):190-6. [Article]
Med-Psych Drug-Drug Interactions Update: Triptans [File]

Drug created at June 13, 2005 13:24 / Updated at June 27, 2022 14:55

Rizatriptan

Identification

Structure for Rizatriptan (DB00953)

Pharmacology

Interactions

Products

Categories

Chemical Identifiers

References

Clinical Trials

Pharmacoeconomics

Properties

Spectra

Targets

References

References

References

Enzymes

References